 Home > Active Ingredient News > Blood System > Professor Ma Jun of World Lymphoma Day: Innovation continues to explore, lymphoma diagnosis and treatment has a long way to go, and the future can be expected

Professor Ma Jun of World Lymphoma Day: Innovation continues to explore, lymphoma diagnosis and treatment has a long way to go, and the future can be expected

 Last Update: 2022-10-03
 Source: Internet
 Author: User

Tags

amino acid treatment

sickle cell disease diagnosis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

15 September 2022 is the 19th World Lymphoma Day

01The aging of the population has intensified, and the incidence of lymphoma has increased

In the past decade, the incidence of lymphoma in China has also shown an upward trend

02 New drugs have emerged, and the efficacy of lymphoma has been continuously improved

At present, in addition to chemotherapy and radiotherapy, the treatment methods of lymphoma also include new immunotherapy therapies such as monoclonal antibodies, immune checkpoint inhibitors and small molecule targeted drugs and cell drugs

03 Take the road of Chinese characteristics, grasp the norms on the one hand, and grasp innovation on the other

The "Healthy China 2030" planning outline clearly states that by 2030, the overall 5-year survival rate of cancer should be increased by 15%, and to achieve this goal, we need to further improve the level of

In addition, China has entered the era of innovative drugs, only innovation can have a future of tumor treatment, only innovative drugs can make cancer patients live longer, get the hope

Professor Ma Jun

Chief physician, professor, doctoral supervisor
Director of Harbin Institute of Hematology and Oncology
Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO).
Vice Chairman of the Asian Society of Clinical Oncology
Chairman of the Leukemia Expert Committee of the Chinese Society of Clinical Oncology
Leader of the expert group of lymphoma specialty construction project of the National Health Commission Capacity Building and Continuing Education Center
Honorary Consultant of Nursing Group of Lymphoma Expert Committee of Chinese Society of Clinical Oncology
In 1979, he went to the Faculty of Medicine, the University of Tokyo, Japan, and has been committed to the diagnosis and treatment of benign and malignant diseases of the blood system, especially in the treatment of leukemia and lymphoma
.

In 1982, the in vitro pluripotent hematopoietic progenitor cell culture system was first established in China to fill the domestic gap
.

Since 1983, more than 1,200 cases of acute promyelocytic leukemia have been treated with retinoic acid and arsenic trioxide sequential therapy, with a 10-year disease-free survival rate of 85%, reaching the international advanced level
.

He has published more than 200 papers and more than 40 monographs in domestic and foreign journals, and won 20 national, provincial and municipal science and technology awards
.

He has undertaken 8 major national 863 scientific research projects and 25 provincial and municipal scientific research projects
.

Editor: Mia Typesetting: Moly Execution: Moly

Poke "Read the original article" to see more

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.